Fig. 2From: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis(A–F) Forest plot showing the observed outcomes and the estimate of the common effect models for MI, ACS hospitalization, Need for Revascularization, Cerebrovascular Accidents, all-cause mortality, and Cardiovascular Mortality [16, 21, 23, 26]Back to article page
